Boston Scientific Corp BSX
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1992-05-19 |
| Shares Out. | 1,486,360,000 |
| Website | bostonscientific.com/en-US/Home.html ↗ |
| Phone | 13026365400 |
| Employees | 59,000 |
| Revenue | $5.20B |
| Gross Profit | $3.61B |
| Net Income | $1.34B |
| Free Cash Flow | $3.48B |
| Total Assets | $44.35B |
| Total Liabilities | $18.25B |
| Equity | $26.10B |
About Boston Scientific Corp
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Boston Scientific Corp is a publicly traded company under the ticker symbol BSX on the NEW YORK STOCK EXCHANGE, INC., operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
39 analysts (2026-07-01)

